Home › Funds › Affinity Asset Advisors, LLC › EPRX
Affinity Asset Advisors, LLC position in EPRX
EUPRAXIA PHARMACEUTICALS INC · Health Care
Affinity Asset Advisors, LLC reported holding 1,716,320 shares of EPRX (EUPRAXIA PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$15.6M, representing 0.73% of its reported portfolio and ranking #36 among its reported holdings. Affinity Asset Advisors, LLC has disclosed EPRX holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Affinity Asset Advisors, LLC's EPRX position evolved
Affinity Asset Advisors, LLC first disclosed a stake in EPRX in Q3 2025 at 300,000 shares (US$1.8M). The position peaked in Q3 2026 at 1,716,320 shares, worth US$15.6M. Across 5 filings, Affinity Asset Advisors, LLC increased the stake 3 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 1,716,320 shares valued at US$15.6M — an increase of 66,320 shares quarter over quarter.. Notable position changes include a 430% increase in Q1 2026 (shares fell 9% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 300.00K | $1.77M | New |
| Q4 2025 | 300.00K | $2.27M | Hold |
| Q1 2026 | 1.59M | $11.50M | Add |
| Q2 2026 | 1.65M | $10.91M | Add |
| Q3 2026 | 1.72M | $15.62M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About EPRX and 13F data
EPRX (EUPRAXIA PHARMACEUTICALS INC) is a Health Care company. 71 other funds we track also report a position in EPRX — the largest reported positions include Vivo Capital, LLC (US$12.3M), PFM Health Sciences, LP (US$8.0M), GREAT POINT PARTNERS LLC (US$7.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding EPRX
- Vivo Capital, LLC 1.35M sh · $12.29M · Q3 2026
- PFM Health Sciences, LP 1.21M sh · $8.00M · Q2 2026
- GREAT POINT PARTNERS LLC 1.20M sh · $7.93M · Q2 2026
- Ikarian Capital, LLC 809.74K sh · $5.35M · Q2 2026
- Redmile Group, LLC 611.40K sh · $4.04M · Q2 2026
- Seven Fleet Capital Management LP 610.78K sh · $4.04M · Q2 2026
- Aisling Capital Management LP 325.00K sh · $2.96M · Q3 2026
- Velan Capital Investment Management LP 352.00K sh · $2.33M · Q2 2026
- Ally Bridge Group (NY) LLC 252.18K sh · $1.67M · Q2 2026
- Delaney Capital Management Ltd. 112.40K sh · $1.03M · Q3 2026
- Lynx1 Capital Management LP 10.00K sh · $66.10K · Q2 2026
More on Affinity Asset Advisors, LLC
FAQ
How long has Affinity Asset Advisors, LLC held EPRX?
Affinity Asset Advisors, LLC has disclosed EPRX holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
What is Affinity Asset Advisors, LLC's current position in EPRX?
As of Q3 2026, Affinity Asset Advisors, LLC holds 1.72M shares of EPRX (EUPRAXIA PHARMACEUTICALS INC), valued at $15.62M, representing 0.73% of its reported portfolio and ranking #36.
Has Affinity Asset Advisors, LLC been buying or selling EPRX?
In the latest 13F filing (Q3 2026), Affinity Asset Advisors, LLC increased its position in EPRX. The position peaked in Q3 2026 at 1.72M shares.
Which other funds hold EPRX?
Other major institutional holders of EPRX include Vivo Capital, LLC, PFM Health Sciences, LP, GREAT POINT PARTNERS LLC, among 71 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.